Investigational drug · Phase 2
KN046
Also called: Recombinant Humanized PD-L1, CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Cancer, Advanced Non-small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
29
Any phase or sponsor naming "KN046"
First trial start
2022
Jul 26, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KN046", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Cancer
- Advanced Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "KN046" as an intervention, largest first.
- KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerPivotal-lookingStatus unknown
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT04474119 · 482 participants · Start Sep 14, 2020 · Primary completion Aug 30, 2022
Drug: KN046; KN046 placebo · For: Squamous Non-small-cell Lung Cancer
Sites: Shanghai, China
- KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.Pivotal-lookingStatus unknown
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT05149326 · 408 participants (planned) · Start Jan 20, 2022 · Primary completion Apr 30, 2024
Drug: KN046; placebo · For: Advanced Pancreatic Ductal Adenocarcinoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 65 sites in all
Suzhou Kintor Pharmaceutical Inc,Industry
NCT04984668 · 216 participants (planned) · Start Nov 2, 2021 · Primary completion Apr 2025
Drug: GT90001+KN046; GT90001+KN046 and 3 more · For: Solid Tumor
Sites: Tainan, Taiwan
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT03733951 · 139 participants · Start Dec 18, 2018 · Primary completion Jan 3, 2023
Drug: KN046 · For: Advanced Solid Tumors; Lymphoma
Sites: Fuzhou, China; Xiamen, China; Guangzhou, China · 13 sites in all
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT03838848 · 120 participants · Start May 5, 2019 · Primary completion Jul 30, 2022
Drug: KN046; KN046 and 4 more · For: Stage IV Non-small Cell Lung Cancer
Sites: Shanghai, China
- A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid TumorsStatus unknown
Maxinovel Pty., Ltd.Industry
NCT05425602 · 108 participants (planned) · Start Jul 31, 2022 · Primary completion Dec 30, 2023
Drug: MAX-40279-01: 50mg/70mg · For: Advanced / Metastatic Solid Tumors
- Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid TumorsCompleted
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT04521179 · 102 participants · Start Dec 7, 2020 · Primary completion Jan 12, 2022
Drug: KN026 combination · For: HER2-positive Solid Tumors
Sites: Beijing, China
Shanghai Chest HospitalAcademic, hospital or other
NCT03927495 · 100 participants (planned) · Start May 22, 2019 · Primary completion Jun 30, 2021
Drug: KN046; KN046 · For: Esophageal Squamous Cell Carcinoma
Sites: Suzhou, China
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT04469725 · 95 participants · Start Dec 2, 2020 · Primary completion Jul 7, 2023
Drug: KN046 · For: Thymic Carcinoma
Sites: Shanghai, China
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT05420220 · 95 participants · Start Jul 26, 2022 · Primary completion Dec 31, 2024
Drug: KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection) · For: Advanced Non-small Cell Lung Cancer
Sites: Hefei, China; Guangzhou, China; Linyi, China · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Case Report: Isolated leptomeningeal relapse after systemic control in PALB2-altered pancreatic cancer.
Yuan J, Xu Y, Zhou Q, et al. · Front Med (Lausanne) 2026
- Case Report: Sustained complete response achieved in a patient with advanced HER-2 positive gastric cancer after 4 years of chemotherapy-free treatment.
Tong X, Peng J, Liu B · Front Oncol 2026
- First case report of immune checkpoint inhibitor-related pneumonitis triggered by bispecific antibody (anti-PD-L1 and anti-CTLA-4) in a patient with non-small cell lung cancer: case report.
Sun H, Liu Y, Chen Z, et al. · Transl Lung Cancer Res 2025
- Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial.
Liu J, Song C, Yang Y, et al. · Clin Cancer Res 2025
- Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer.
Wen J, Cui W, Yin X, et al. · Cancer Biol Med 2025
- Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study.
Liu D, Gong J, Li J, et al. · Signal Transduct Target Ther 2025
Also in development for Pancreatic Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- HRS-7058Phase 35 trials
Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.